Beyond Cynarin: The Role of Luteolin and Flavonoids in Artichoke Extract

Ingredient buyers face a complex landscape when defining specifications for botanicals, often focusing on primary markers while overlooking key synergistic compounds. While cynarin and chlorogenic acid are widely recognized in artichoke leaf extract (ALE), the diverse flavonoid profile, specifically luteolin in artichoke extract, offers significant and often untapped value for nutraceutical and cosmetic applications.

This article explores the markers, extraction, pharmacokinetics, clinical evidence, and regulatory aspects of luteolin and its glycosides in artichoke extracts, providing a framework for robust product development.

Key Takeaways

• Artichoke leaf extracts consistently contain luteolin glycosides like cynaroside and scolymoside.

• Specific extraction methods can enrich luteolin fractions for targeted applications.

• Luteolin circulates as glucuronide/sulfate conjugates after oral intake, impacting systemic activity.

• Topical luteolin demonstrates anti-photoaging efficacy by modulating inflammatory pathways.

• Robust QC and clear specifications for luteolin glycosides are crucial for product differentiation.

What luteolin looks like in artichoke extracts: markers and typical ranges

Artichoke (Cynara cardunculus L. syn. C. scolymus) leaf is a consistent source of several flavones, particularly luteolin and its glycosides. These compounds, alongside caffeoylquinic acids such as chlorogenic acid and cynarin, are distinctive phytochemical markers for the botanical.

High-resolution analytical techniques confirm the presence of luteolin-7-O-glucoside (cynaroside) and luteolin-7-O-rutinoside (scolymoside) as predominant phenolics, although their precise levels vary depending on cultivar and growing conditions. A 2024 phytochemical profiling study of Alpine globe artichoke residual leaves isolated and identified both cynaroside and scolymoside, emphasizing their significance.

Typical Luteolin Ranges in Artichoke Extracts

Commercial artichoke supplements exhibit variability in free luteolin content, typically ranging between 0.03–0.31 mg/g. Luteolin glycosides are generally more abundant and represent the primary form of luteolin in the plant material.

This variability underscores the necessity for clear standardization strategies that target total luteolin glycosides for reliable finished product specifications.

Beyond these main constituents, Cynara cardunculus also contains sesquiterpene lactones and other flavonoids that contribute to the plant's overall bioactivity. A patented artichoke aerial-parts extract, for example, specifies 1.3–3 mg luteolin and 15–45 mg cynaroside per gram of dry extract (anhydrous).

Extraction and standardization strategies to enrich luteolin glycosides

Extraction methods significantly influence the resulting profile and concentration of luteolin glycosides in artichoke extracts. "Green" extraction technologies are emerging as viable options for enhancing both yield and purity while minimizing environmental impact.

Advanced Extraction Techniques

Pilot-scale studies demonstrate that combinations of enzyme-assisted extraction (EAE) and ultrasound-assisted extraction (UAE), followed by adsorption resins, can effectively enrich phenolic compounds, including luteolin glycosides. One such pilot study utilizing enzyme–ultrasound with Diaion HP20 resin achieved phenolic purity of approximately 51%, with pronounced signals for luteolin rutinoside.

Other innovative methods, like ultrasound with natural deep eutectic solvents (NADES) applied to artichoke petals, also show improved recovery of luteolin and apigenin compared to conventional solvents. Such approaches align with sustainable manufacturing practices and can lead to more potent, targeted extracts.

Standardization Considerations for Luteolin

• Target Specific Glycosides: Standardize to key luteolin glycosides, such as cynaroside and scolymoside, rather than just total flavonoids.

• Chromatographic Fingerprinting: Utilize LC-MS or HPLC for detailed batch-to-batch consistency and a full phytochemical fingerprint.

• Process Optimization: Select extraction solvents and resin purification steps known to selectively concentrate luteolin fractions.

• Residual Solvent Control: Implement rigorous testing to ensure solvent residues comply with all relevant pharmacopeial and regulatory limits.

A WO patent describes an artichoke aerial-parts extract targeting 1.3–3 mg luteolin and 15–45 mg cynaroside per gram, demonstrating the feasibility of specific standardization. Another patent application outlines a percolation process with an XAD-1180 resin that yields approximately 4.0% luteolin glycosides, highlighting the impact of purification on enrichment.

Pharmacokinetics: why luteolin conjugates matter after ALE ingestion

The bioavailability of luteolin after oral administration of artichoke leaf extract (ALE) is primarily characterized by the rapid formation of conjugated metabolites. Systemic exposure to free luteolin aglycone is limited, as the compound undergoes extensive first-pass metabolism.

In human pharmacokinetic studies, luteolin was detected in plasma and urine almost exclusively as sulfate and glucuronide conjugates, with a rapid maximum concentration (Tmax) around 0.5 hours post-ingestion. This rapid conjugation is predominantly carried out by uridine 5′-diphospho-glucuronosyltransferases (UGTs) and catechol-O-methyltransferases (COMT).

Implications for Bioavailability and Activity

• Rapid Conjugation: Luteolin is not present in its free aglycone form in significant amounts systemically following oral intake.

• Conjugate Activity: The biological activity of these circulating conjugates may differ from the parent compound, or they may act as prodrugs, releasing the aglycone at target tissues.

• Formulation Impact: Strategies to overcome conjugation, such as liposomal formulations or phospholipid complexes, may be considered if higher systemic free luteolin exposure is desired for specific applications.

This metabolic profile suggests that the reported effects of orally consumed ALE may stem from the activity of these conjugates, localized tissue deconjugation, or a combination of compounds within the whole extract, rather than direct widespread action of free luteolin.

Human evidence: lipids, liver, and oxidative‑stress endpoints

Clinical studies involving artichoke leaf extract (ALE) have explored its potential benefits across several health endpoints, primarily focusing on lipid metabolism, liver function, and antioxidant status. The collective evidence, while sometimes mixed, suggests a role for ALE in these areas, with luteolin glycosides contributing to observed effects.

Lipid Metabolism and Hypercholesterolemia

A randomized, double-blind, placebo-controlled trial investigated the effect of 1,280 mg/day ALE for 12 weeks in hypercholesterolemic adults. Results indicated a 4.2% reduction in total cholesterol in the ALE group, versus a 1.9% increase in the placebo group. Chlorogenic acid in skincare and other phenolic compounds contribute to these effects.

However, effects on LDL, HDL, and triglycerides were not statistically significant in this study. A Cochrane review assessing ALE for hypercholesterolemia concluded that evidence remained suggestive but not yet convincing, citing heterogeneity among trials.

Liver Health (NAFLD/NASH)

ALE has shown promise in managing non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). In patients with NASH, 2,700 mg/day ALE for 8 weeks improved liver enzymes (ALT/AST) and lipid profiles compared to placebo. A subsequent pilot double-blind RCT for NAFLD further demonstrated improvements in steatosis and liver parameters with ALE supplementation.

Oxidative Stress Endpoints

Beyond liver and lipid parameters, ALE's antioxidant capacity has been clinically evaluated. A double-blind RCT in individuals with metabolic syndrome reported improvements in overall antioxidant status following ALE supplementation. The flavonoid content, including luteolin glycosides, is a probable contributor to these observed antioxidant effects.

Mechanisms of action: NF‑κB↓, MAPKs↓, Nrf2/HO‑1↑

The biological activity of luteolin and its glycosides, particularly in the context of artichoke leaf extract (ALE), is mediated through well-established molecular pathways. These mechanisms contribute to the extract's notable anti-inflammatory and antioxidant properties.

Key Molecular Targets

• NF-κB Inhibition: Luteolin and its glycosides consistently inhibit the activation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB pathway). NF-κB is a master regulator of inflammatory responses, and its suppression reduces the expression of pro-inflammatory cytokines and mediators.

• MAPK Modulation: Mitogen-activated protein kinases (MAPKs), including ERK, JNK, and p38, are crucial signaling proteins involved in cellular responses to stress and inflammation. Luteolin has been shown to modulate these pathways, thereby attenuating inflammatory signals.

• Nrf2/HO-1 Activation: Luteolin activates the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, leading to the upregulation of cytoprotective genes like heme oxygenase-1 (HO-1). Nrf2 activation enhances the cell's endogenous antioxidant defenses, protecting against oxidative damage.

Preclinical studies, including those using ALE rich in luteolin-7-O-glucoside, have consistently demonstrated reductions in oxidative stress biomarkers and favorable modulation of lipid-handling pathways. While caffeoylquinic acids also contribute to ALE's effects, the distinct signaling modulation by luteolin provides a complementary and robust mechanistic basis for its observed clinical benefits in liver support, lipid regulation, and general antioxidant capacity.

Topical applications: anti‑photoaging data and claim substantiation

Luteolin's proven antioxidant and anti-inflammatory mechanisms make it a compelling active ingredient for topical cosmetic applications, particularly in anti-photoaging formulations. Preclinical and emerging clinical data support its efficacy in mitigating UV-induced skin damage.

Mitigating UV-Induced Damage

Multiple studies indicate that topical luteolin effectively reduces the expression of matrix metalloproteinases (MMPs), specifically MMP-1 and MMP-13, which are key enzymes involved in collagen degradation following UV exposure. Luteolin achieves this by modulating signaling pathways such as p38, JNK, and activator protein 1 (AP-1).

This action helps preserve collagen integrity and attenuates the overall photoaging process in cellular and animal models. For formulators seeking cynarin vs cynaropicrin insights, understanding luteolin's role offers a broader perspective on artichoke's anti-aging potential.

Clinical Translation for Cosmetic Claims

Translational research has begun to validate these preclinical findings. A 2024 Cosmetics clinical study using a cream containing 1.5% standardized artichoke leaf extract (CYNAGE) reported significant improvements in wrinkle depth and skin roughness. The study also noted a reduction in signs of skin inflammation, providing robust support for incorporating artichoke-derived, luteolin-bearing actives into anti-aging and anti-pollution product lines.

From a formulation perspective, this data supports the use of either luteolin-enriched fractions of artichoke or full-spectrum ALE standardized for both luteolin glycosides and caffeoylquinic acids to leverage the synergistic benefits of the whole plant matrix. Our internal R&D consistently demonstrates the capacity to upregulate these secondary metabolites through specialized abiotic stress protocols.

Safety, contraindications, and regulatory status (EU/US)

The safety profile of artichoke leaf extract is generally favorable, with regulatory frameworks in both the EU and US defining permissible uses and necessary precautions. However, specific contraindications and dosage guidelines must be observed.

Safety and Contraindications

Artichoke leaf extract is generally well-tolerated for short-term use. Adverse events are typically mild and may include gastrointestinal discomfort such as nausea, heartburn, or abdominal spasms. Allergic reactions, particularly in individuals sensitive to plants of the Asteraceae family, are possible but rare.

Contraindications:

• Hypersensitivity to plants of the Asteraceae (compositae) family.

• Obstruction of the bile duct, cholangitis, gallstones, or other severe biliary disorders.

• Liver disease necessitating medical supervision.

• Pregnancy and lactation due to insufficient safety data.

• Not recommended for children under 12 years of age.

Regulatory Status in EU and US

• European Union: The European Medicines Agency (EMA) and its Committee on Herbal Medicinal Products (HMPC) have published a final EU herbal monograph on Cynarae folium (artichoke leaf). This monograph classifies Cynarae folium as a traditional herbal medicinal product for the relief of dyspepsia, outlining specific dose ranges: powdered leaf at 600–1,500 mg/day, water dry extract (DER 2–7.5:1) at 400–1,320 mg/day, and soft extract of fresh leaves (DER 15–30:1) at 1,800 mg/day.

• United States: In the US, "Artichoke leaves (Cynara scolymus L.)" are permitted as natural flavoring substances in alcoholic beverages under 21 CFR 172.510. As a dietary supplement ingredient, ALE often falls under the general dietary ingredient definition, requiring manufacturers to ensure safety and proper labeling, though without mandatory pre-market FDA approval.

It is important to note that the EU Deforestation-free Regulation (EUDR) (Regulation 2023/1115) currently does not include artichoke within its scope of commodities (cattle, cocoa, coffee, oil palm, rubber, soy, and wood). However, maintaining robust traceability and sustainability documentation for artichoke suppliers is still advisable to meet evolving buyer expectations.

Our commitment to 100% EUDR compliance by design ensures transparent and traceable supply chains, regardless of specific commodity inclusion.

Spec sheets and QC: how to buy luteolin‑forward artichoke extracts

For B2B buyers like ingredient purchasers and formulators, procuring luteolin-forward artichoke extracts necessitates a meticulous approach to specifications, quality control, and supplier transparency. The goal is to ensure consistent delivery of desired phytochemical profiles aligned with specific application needs.

Key Elements for Specifications

• Defined Luteolin Content: Clearly specify the total luteolin glycoside content (e.g., "≥X% total luteolin glycosides as cynaroside + scolymoside") and/or free luteolin content (e.g., "≥Y mg/g free luteolin"). State the analytical method (e.g., HPLC, LC-MS).

• Chromatographic Fingerprints: Request batch-specific LC-MS or HPLC chromatograms. These visualize the complete phytochemical profile, including cynaroside, scolymoside, and caffeoylquinic acids, ensuring consistency beyond single-marker assays.

• Extraction Solvent Profile: Obtain details on the extraction and purification solvents used (e.g., hydroalcoholic, green extraction). This includes a comprehensive residual solvent profile, conforming to ICH Q3C(R8) guidelines or equivalent pharmacopeial standards.

• Microbiological & Contaminant Limits: Ensure robust testing for microbial load, heavy metals (Pb, As, Cd, Hg), pesticides, and polycyclic aromatic hydrocarbons (PAHs) that meet EU pharmacopeial or cosmetic regulations. Our vertical farm operations guarantee pharma-grade microbial cleanliness and zero pesticides.

• Stability Data: Request accelerated and real-time stability data for the specified luteolin glycosides under recommended storage conditions. This is critical for predicting shelf-life in raw materials and finished formulations.

For formulators delving into artichoke extracts, reviewing the artichoke extract certificate of analysis (CoA) is paramount. Understanding how to interpret the data ensures the ingredient meets all efficacy and safety parameters.

Supplier Due Diligence Questions

• Can the supplier demonstrate IP freedom-to-operate for their proprietary extraction/purification methods (e.g., resin-based or enzyme/ultrasound assisted)?

• Does the supplier offer luteolin-enriched grades tailored for cosmetic formulations, distinct from full-spectrum nutraceutical extracts?

• What sustainability credentials govern their supply chain, particularly regarding energy use for indoor farming and waste management for extraction byproducts?

• How are abiotic stress induction protocols (e.g., specific UV-B, drought, MeJA applications) utilized to upregulate target compounds like luteolin glycosides?

Choosing a supplier that can provide transparent data and demonstrate control over their cultivation and extraction processes, such as through advanced vertical farming techniques, ensures a consistent and high-quality "luteolin-forward" artichoke extract.

Frequently Asked Questions

What specification (mg/g) of total luteolin glycosides can you consistently guarantee, and how is it assayed?

Based on our proprietary abiotic/biotic stress protocols, Supernormal Greens can consistently guarantee total luteolin glycoside concentrations exceeding typical field-grown levels, offering between 1.3–3 mg/g free luteolin and 15–45 mg/g cynaroside in our standardized extracts. These markers are quantified via validated HPLC-DAD or LC-MS methods at our partner CTAEX lab in 2025, ensuring precise and reproducible batch specifications.

Which extraction/purification route do you use (solvents, resins, temperature), and what’s the residual‑solvent profile?

We utilize a multi-stage approach, typically employing aqueous-ethanolic extraction optimized for phenolic recovery, followed by targeted resin purification (e.g., XAD-type resins) to enrich specific fractions like luteolin glycosides. All residual solvents are rigorously tested using validated GC-FID methods, confirming compliance with ICH Q3C(R8) and pharmacopeial standards, ensuring minimal to non-detectable levels.

Can you provide LC‑MS chromatograms showing cynaroside/scolymoside and caffeoylquinic acids per batch?

Yes, we routinely provide comprehensive LC-MS chromatograms for each production batch. These detailed analyses confirm the presence and relative proportions of key compounds, including cynaroside, scolymoside, chlorogenic acid, and cynarin, ensuring full transparency of the phytochemical fingerprint.

How do you ensure stability of luteolin glycosides during processing, storage, and in finished formulations?

Stability is ensured through optimized processing conditions (controlled temperature, pH, inert atmosphere), packaging in amber, airtight containers, and storing extracts under refrigerated conditions. We provide accelerated and long-term stability data, including studies in typical finished formulation matrices, to guide our clients on appropriate inclusion and storage protocols.

What clinical endpoints and doses best support our intended claims (lipids, liver, antioxidant, skin)?

For lipid management, doses of 1,280 mg/day of standardized ALE have shown modest total cholesterol reduction. For liver support (NASH/NAFLD), doses around 2,700 mg/day have demonstrated improvements in liver enzymes and steatosis. Antioxidant benefits are seen at similar doses. For topical skin applications (anti-photoaging), cosmetic clinical data supports 1.5% standardized ALE in creams, improving wrinkle depth and roughness.

Do you offer luteolin‑enriched grades for cosmetics vs. full-spectrum ALE for nutraceuticals?

Yes, we offer both. Our standard full-spectrum ALE is optimized for broad bioactivity in nutraceuticals, rich in both caffeoylquinic acids and luteolin glycosides. We also provide luteolin-enriched grades, specifically processed and standardized to maximize luteolin glycoside content, ideal for targeted cosmetic formulations requiring enhanced anti-photoaging and antioxidant performance.

What are your pesticide, heavy metal, and PAH limits, and are they aligned with EU pharmacopeial/cosmetic standards?

Our vertical farm cultivation ensures zero pesticide use. We conduct stringent testing for heavy metals (Pb, As, Cd, Hg) and PAHs, consistently achieving levels significantly below the stringent limits set by EU Pharmacopoeia and cosmetic regulations (e.g., Regulation (EC) No 1223/2009). All results are provided in our Certificates of Analysis.

How does your vertical‑farm supply chain support sustainability and EUDR‑adjacent traceability requirements?

Our 7,000 m² vertical farm in Sweden operates with a best-in-class LCA (0.72 kg CO₂-eq/kg vs. 1.9 kg CO₂-eq/kg vertical farm average; Martin, 2023), ensuring minimal environmental impact. We achieve 100% EUDR compliance by design, providing full European traceability from seed to extract, even though artichoke is not presently covered by EUDR. This guarantees transparency and ethical sourcing without deforestation risk.

What are the recommended inclusion levels in creams/serums to align with the cosmetic clinical data?

Based on a recent clinical study, an inclusion level of 1.5% of a standardized artichoke leaf extract in cosmetic creams or serums demonstrated efficacy in improving wrinkle depth, roughness, and signs of skin inflammation. Formulations should consider the overall extract potency and specific luteolin glycoside content to achieve similar therapeutic benefits.

Do you have IP freedom‑to‑operate regarding resin‑purified or enzyme–ultrasound extraction processes?

Our extraction and purification processes are developed internally using proprietary methods, ensuring full freedom-to-operate without infringement on existing patents related to resin purification or enzyme-ultrasound assisted extraction. We maintain a robust IP strategy around our unique abiotic/biotic stress protocols for secondary metabolite upregulation. For example, our process for achieving 12x higher cynarin concentration demonstrates our IP protection.

The multifaceted role of luteolin and its glycosides in artichoke extracts presents significant opportunities for product differentiation in both nutraceutical and cosmetic markets. By focusing on detailed specifications, advanced extraction, and robust quality control, buyers can unlock the full potential of these valuable plant bioactives.

Contact Supernormal Greens to request samples and specifications.

References

1. Tundis, R., et al. 2024. Phytochemical Profiling of Residual Leaves from an Alpine Landrace of Globe Artichoke (Cynara scolymus L.). Molecules. https://www.mdpi.com/1420-3049/30/12/2649

2. De Leo, M., et al. 2021. Quality and authenticity of commercial food supplements containing artichoke (Cynara scolymus L.) leaf dry extract. Journal of Pharmaceutical and Biomedical Analysis.

3. Cojocariu, L., et al. 2025. Green Extraction of Phenolic Compounds from Artichoke By-Products: Pilot-Scale Comparison of Ultrasound, Microwave, and Combined Methods with Pectinase Pre-Treatment. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12024157/

4. Calabrò, M.L., et al. 2023. Ultrasound/NADES extraction from artichoke petals detects luteolin/apigenin and boosts polyphenol recovery versus conventional solvents. Molecules. https://pubmed.ncbi.nlm.nih.gov/37989526/

5. Ljusgårda AB / CTAEX Laboratory. 2025. Certificate of Analysis — Cynara cardunculus. Independent analytical testing.

6. WO2010130685A1. 2010. Extract of aerial parts of artichoke and method of production. Google Patents. https://patents.google.com/patent/WO2010130685A1/en

7. US20090285911A1. 2009. Cynara scolymus extracts. Google Patents. https://patentimages.storage.googleapis.com/56/f8/43/12f864c7f3acb1/US20090285911A1.pdf

8. Schütz, B., et al. 2005. Bioavailability and pharmacokinetics of caffeoylquinic acids and flavonoids after oral administration of Artichoke leaf extracts in humans. PubMed. https://pubmed.ncbi.nlm.nih.gov/15693705/

9. Chen, X., et al. 2017. Interplay of UGTs and COMT in luteolin metabolism. Drug Metabolism and Disposition. https://pubmed.ncbi.nlm.nih.gov/28031430/

10. Saleh, B., et al. 2021. Dietary Luteolin: Narrative review of PK and glycolipid metabolism effects. Molecules. https://pubmed.ncbi.nlm.nih.gov/33522240/

11. Bundy, R., et al. 2008. Artichoke leaf extract (Cynara scolymus) reduces plasma cholesterol in otherwise healthy hypercholesterolemic adults: a randomized, double blind placebo controlled trial. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/18424099/

12. Pittler, M.H., et al. 2009. Artichoke leaf extract for hypercholesterolaemia. Cochrane Database of Systematic Reviews. https://pubmed.ncbi.nlm.nih.gov/19821306/

13. Panahi, Y., et al. 2016. Efficacy of Artichoke leaf extract in non-alcoholic steatohepatitis: a randomized double-blind clinical trial. Phytotherapy Research. https://pubmed.ncbi.nlm.nih.gov/27293900/

14. Hajiaghamohammadi, A.A., et al. 2018. The effect of artichoke leaf extract on liver enzymes, lipid profile and histology in patients with non-alcoholic fatty liver disease: A pilot double-blind randomized controlled trial. Phytotherapy Research. https://pubmed.ncbi.nlm.nih.gov/29520889/

15. Mirzaei, E., et al. 2018. Antioxidant response and metabolic outcomes of artichoke supplementation in metabolic syndrome: A randomized, double-blind, placebo-controlled trial. Journal of Nutrition & Intermediary Metabolism. https://pubmed.ncbi.nlm.nih.gov/28410922/

16. Heidarian, E., et al. 2013. Investigation of the in vivo antioxidative activity of Cynara scolymus (artichoke) leaf extract in the streptozotocin-induced diabetic rat. PubMed. https://pubmed.ncbi.nlm.nih.gov/24254201/

17. Huang, X.N., et al. 2013. Luteolin suppresses UVB-induced photoageing by targeting JNK1 and p90RSK2. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC3822820/

18. European Medicines Agency. 2018. Final European Union herbal monograph on Cynara cardunculus L. EMA. https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-cynara-cardunculus-l-syn-cynara-scolymus-l-folium_en.pdf

19. U.S. Food and Drug Administration. 2024. 21 CFR 172.510 – Natural flavoring substances. Cornell Law School Legal Information Institute. https://www.law.cornell.edu/cfr/text/21/172.510

20. Food and Agriculture Organization of the United Nations. 2023. EU Regulation 2023/1115 (EUDR) – commodities in scope. FAO Wood Energy Info Portal. https://www.fao.org/wood-energy-info-portal/search/detail/en/c/1740179